Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.

Gray NS, Pilowsky LS, Gray JA, Kerwin RW.

Schizophr Res. 1995 Sep;17(1):95-107.

PMID:
8541255
[PubMed - indexed for MEDLINE]
2.

D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.

Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW.

Br J Psychiatry. 1994 Jan;164(1):16-26.

PMID:
8137105
[PubMed - indexed for MEDLINE]
3.

Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia.

Yang YK, Yeh TL, Chiu NT, Lee IH, Chen PS, Lee LC, Jeffries KJ.

Psychiatry Res. 2004 Sep 15;131(3):209-16.

PMID:
15465290
[PubMed - indexed for MEDLINE]
4.

Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia: an [123I]iodobenzamide single photon emission computed tomography study.

Schröder J, Bubeck B, Silvestri S, Demisch S, Sauer H.

Psychiatry Res. 1997 Sep 29;75(2):115-23.

PMID:
9351493
[PubMed - indexed for MEDLINE]
5.

Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study.

Parellada E, Lomeña F, Catafau AM, Bernardo M, Font M, Fernández-Egea E, Pavía J, Gutierrez F.

Psychiatry Res. 2004 Jan 15;130(1):79-84.

PMID:
14972370
[PubMed - indexed for MEDLINE]
6.

Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study.

Lomeña F, Catafau AM, Parellada E, Bernardo M, Font M, Gutiérrez F, Pavía J.

Psychopharmacology (Berl). 2004 Mar;172(2):165-9. Epub 2003 Nov 18.

PMID:
14624330
[PubMed - indexed for MEDLINE]
7.

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.

Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.

Am J Psychiatry. 1996 Feb;153(2):183-90.

PMID:
8561197
[PubMed - indexed for MEDLINE]
8.

Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study.

Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW.

Psychol Med. 1993 Aug;23(3):791-7.

PMID:
7901865
[PubMed - indexed for MEDLINE]
9.

Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia.

Pedro BM, Pilowsky LS, Costa DC, Hemsley DR, Ell PJ, Verhoeff NP, Kerwin RW, Gray NS.

Psychol Med. 1994 May;24(2):423-9.

PMID:
8084937
[PubMed - indexed for MEDLINE]
10.

Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls.

Yang YK, Chiu NT, Chen CC, Chen M, Yeh TL, Lee IH.

Psychiatry Res. 2003 Jul 30;123(3):191-7.

PMID:
12928107
[PubMed - indexed for MEDLINE]
11.

Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.

Volk S, Maul FD, Hör G, Schreiner M, Weppner M, Holzmann T, Pflug B.

Psychiatry Res. 1994 Jun;55(2):111-8.

PMID:
10711799
[PubMed - indexed for MEDLINE]
12.

A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

Tibbo P, Silverstone PH, McEwan AJ, Scott J, Joshua A, Golberg K.

J Psychiatry Neurosci. 1997 Jan;22(1):39-45.

PMID:
9002391
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, Wegelius U.

Arch Gen Psychiatry. 1994 Feb;51(2):116-23.

PMID:
7905257
[PubMed - indexed for MEDLINE]
14.

In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.

Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K.

Eur J Nucl Med. 1999 Aug;26(8):862-8.

PMID:
10436199
[PubMed - indexed for MEDLINE]
15.
16.

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.

Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gómez JC, López-Carrero C, Gutiérrez F, Pavía J, Salamero M.

Psychiatry Res. 2001 Aug 25;107(2):87-97.

PMID:
11530275
[PubMed - indexed for MEDLINE]
17.

Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.

Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.

J Nucl Med. 1998 Jul;39(7):1138-42.

PMID:
9669383
[PubMed - indexed for MEDLINE]
Free Article
18.

Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.

Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH; SPECT study.

Am J Psychiatry. 2004 Aug;161(8):1496-8.

PMID:
15285982
[PubMed - indexed for MEDLINE]
19.

Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.

Pickar D, Su TP, Weinberger DR, Coppola R, Malhotra AK, Knable MB, Lee KS, Gorey J, Bartko JJ, Breier A, Hsiao J.

Am J Psychiatry. 1996 Dec;153(12):1571-8.

PMID:
8942453
[PubMed - indexed for MEDLINE]
20.

Clinical and psychometric correlates of dopamine D2 binding in depression.

Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP.

Psychol Med. 1997 Nov;27(6):1247-56.

PMID:
9403896
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk